Intrathecal therapy for cancer and nonmalignant pain: Patient selection and patient management

Timothy Deer, Wolfhard Winkelmuller, Serdar Erdine, Marshall Bedder, Kim Burchiel

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Intrathecal drug delivery improves pain relief, reduces suffering, and enhances quality of life in the small proportion of patients who do not respond well to oral analgesics, including oral morphine. Although morphine is the 'gold standard,' and the only drug approved for intrathecal pain therapy in the United States, off-label use of alternative agents appears promising, particularly in patients with neuropathic pain. Careful patient selection and management are significant determinants of successful treatment outcomes. Patient selection criteria for cancer and nonmalignant pain are similar; however, a more comprehensive psychological and social assessment is required for patients with nonmalignant pain. In addition, all patients (those with cancer or nonmalignant pain) must exhibit a positive response to an epidural or intrathecal screening test. A multidisciplinary team approach, involving psychologists, nurses, physical therapists, social workers, and spiritual leaders should be used to manage patients. Current practices for patient selection and management, screening tests, and dosing guidelines for intrathecal drug delivery systems are discussed.

Original languageEnglish (US)
Pages (from-to)55-66
Number of pages12
JournalNeuromodulation
Volume2
Issue number2
DOIs
StatePublished - 1999

Fingerprint

Patient Selection
Pain
Morphine
Psychology
Off-Label Use
Therapeutics
Physical Therapists
Neuralgia
Drug Delivery Systems
Psychological Stress
Pharmaceutical Preparations
Analgesics
Nurses
Quality of Life
Cancer Pain
Guidelines
Neoplasms

Keywords

  • Cancer
  • Cancer pain
  • Intrathecal therapy
  • Nonmalignant pain
  • Opioids

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Neuroscience(all)

Cite this

Intrathecal therapy for cancer and nonmalignant pain : Patient selection and patient management. / Deer, Timothy; Winkelmuller, Wolfhard; Erdine, Serdar; Bedder, Marshall; Burchiel, Kim.

In: Neuromodulation, Vol. 2, No. 2, 1999, p. 55-66.

Research output: Contribution to journalArticle

Deer, Timothy ; Winkelmuller, Wolfhard ; Erdine, Serdar ; Bedder, Marshall ; Burchiel, Kim. / Intrathecal therapy for cancer and nonmalignant pain : Patient selection and patient management. In: Neuromodulation. 1999 ; Vol. 2, No. 2. pp. 55-66.
@article{b70fc99345f04018bfafc521e94df3aa,
title = "Intrathecal therapy for cancer and nonmalignant pain: Patient selection and patient management",
abstract = "Intrathecal drug delivery improves pain relief, reduces suffering, and enhances quality of life in the small proportion of patients who do not respond well to oral analgesics, including oral morphine. Although morphine is the 'gold standard,' and the only drug approved for intrathecal pain therapy in the United States, off-label use of alternative agents appears promising, particularly in patients with neuropathic pain. Careful patient selection and management are significant determinants of successful treatment outcomes. Patient selection criteria for cancer and nonmalignant pain are similar; however, a more comprehensive psychological and social assessment is required for patients with nonmalignant pain. In addition, all patients (those with cancer or nonmalignant pain) must exhibit a positive response to an epidural or intrathecal screening test. A multidisciplinary team approach, involving psychologists, nurses, physical therapists, social workers, and spiritual leaders should be used to manage patients. Current practices for patient selection and management, screening tests, and dosing guidelines for intrathecal drug delivery systems are discussed.",
keywords = "Cancer, Cancer pain, Intrathecal therapy, Nonmalignant pain, Opioids",
author = "Timothy Deer and Wolfhard Winkelmuller and Serdar Erdine and Marshall Bedder and Kim Burchiel",
year = "1999",
doi = "10.1046/j.1525-1403.1999.00055.x",
language = "English (US)",
volume = "2",
pages = "55--66",
journal = "Neuromodulation",
issn = "1094-7159",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Intrathecal therapy for cancer and nonmalignant pain

T2 - Patient selection and patient management

AU - Deer, Timothy

AU - Winkelmuller, Wolfhard

AU - Erdine, Serdar

AU - Bedder, Marshall

AU - Burchiel, Kim

PY - 1999

Y1 - 1999

N2 - Intrathecal drug delivery improves pain relief, reduces suffering, and enhances quality of life in the small proportion of patients who do not respond well to oral analgesics, including oral morphine. Although morphine is the 'gold standard,' and the only drug approved for intrathecal pain therapy in the United States, off-label use of alternative agents appears promising, particularly in patients with neuropathic pain. Careful patient selection and management are significant determinants of successful treatment outcomes. Patient selection criteria for cancer and nonmalignant pain are similar; however, a more comprehensive psychological and social assessment is required for patients with nonmalignant pain. In addition, all patients (those with cancer or nonmalignant pain) must exhibit a positive response to an epidural or intrathecal screening test. A multidisciplinary team approach, involving psychologists, nurses, physical therapists, social workers, and spiritual leaders should be used to manage patients. Current practices for patient selection and management, screening tests, and dosing guidelines for intrathecal drug delivery systems are discussed.

AB - Intrathecal drug delivery improves pain relief, reduces suffering, and enhances quality of life in the small proportion of patients who do not respond well to oral analgesics, including oral morphine. Although morphine is the 'gold standard,' and the only drug approved for intrathecal pain therapy in the United States, off-label use of alternative agents appears promising, particularly in patients with neuropathic pain. Careful patient selection and management are significant determinants of successful treatment outcomes. Patient selection criteria for cancer and nonmalignant pain are similar; however, a more comprehensive psychological and social assessment is required for patients with nonmalignant pain. In addition, all patients (those with cancer or nonmalignant pain) must exhibit a positive response to an epidural or intrathecal screening test. A multidisciplinary team approach, involving psychologists, nurses, physical therapists, social workers, and spiritual leaders should be used to manage patients. Current practices for patient selection and management, screening tests, and dosing guidelines for intrathecal drug delivery systems are discussed.

KW - Cancer

KW - Cancer pain

KW - Intrathecal therapy

KW - Nonmalignant pain

KW - Opioids

UR - http://www.scopus.com/inward/record.url?scp=0033002847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033002847&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1403.1999.00055.x

DO - 10.1046/j.1525-1403.1999.00055.x

M3 - Article

C2 - 22151109

AN - SCOPUS:0033002847

VL - 2

SP - 55

EP - 66

JO - Neuromodulation

JF - Neuromodulation

SN - 1094-7159

IS - 2

ER -